GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET.

A live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. An archived recording will be available for 30 days following the event.

About GlycoMimetics, Inc.

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs--known as glycomimetics--that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231109940316/en/

Investors:
Argot Partners
Leo Vartorella
212-600-1902
[email protected]

Source: GlycoMimetics, Inc.

You May Also Be Interested In

• Infleqtion Collaboration with Japan Moonshot Program Achieves Major Milestone: "Shunkai" Neutral Atom Quantum Computer Now Operational
• Cannabis's MSO's Perfect Storm: Class Actions, RICO & Insurance Denials?
• TowerBrook Capital Partners and Rael Announce Strategic Partnership to Scale Holistic Women's Wellness Brand